Respiratory - Page 1
Stay up to date with the latest Respiratory updates from the global drugdevelopment industryLatest Respiratory Update
Elevation Pharmaceuticals has announced positive results from a Phase 2b study of EP-101 in patients with chronic obstructive pulmonary disease (COPD), a progressive disease comprising...
> read more
IDRI joins Aeras to develop vaccine against tuberculosis
Aeras and the Infectious Disease Research Institute (IDRI) have signed a joint development agreement regarding IDRI's tuberculosis (TB) vaccine candidate,...
Novartis says QVA149 Phase III studies meet primary endpoints
The first three Phase III studies of Novartis' QVA149 (indacaterol 110 mcg/glycopyrronium bromide 50 mcg) have met all the primary endpoints in patients with chronic obstructive pulmonary...
MediciNova concludes patient enrolment in Phase 2 MN-221 study
MediciNova has concluded patient enrolment in its Phase 2 clinical trial (MN-221-CL-007) evaluating the safety and efficacy of MN-221, used for the treatment of acute exacerbations of asthma...
Merck's AIT shows efficacy against ragweed allergy
The Phase III study conducted by Merck has revealed that its investigational allergy immunotherapy tablet (AIT) reduced the total combined score that measured nasal and eye symptoms and use...
Meda MP29-02 shows efficacy in clinical studies
Meda's MP29-02 (Dymista) was found to be well tolerated and effective in three clinical trials conducted in patients with chronic allergic or non-allergic...
Ikaria concludes patient enrollment in iNO pivotal Phase III trial
Ikaria has completed patient enrollment in its pivotal Phase III clinical trial investigating the use of inhaled nitric oxide (iNO) in premature infants with bronchopulmonary dysplasia...
AiCuris reports efficacy data of Letermovir drug
AiCuris' Letermovir (AIC246) has met its primary efficacy endpoints in a Phase 2 trial for the control of human cytomegalovirus (HCMV) prophylaxis in human blood precursor cell (HBPC)...
Ista begins Beposone nasal spray study
Ista Pharmaceuticals' Beposone nasal spray has entered into a Phase II clinical study in conjugation with bepotastine besilate and a steroid for the treatment of the symptoms associated...
Pfizer pneumonia vaccine receives FDA clearance
The US Food and Drug Administration (FDA) has approved the extended use of Pfizer's pneumococcal conjugate vaccine- Prevnar 13 as a single-dose treatment for pneumonia in...
FDA clears Vertex Kalydeco NDA
The US Food and Drug Administration (FDA) has granted Vertex Pharmaceuticals' New Drug Application (NDA) and its request for a six-month Priority Review of its Kalydeco (ivacaftor, VX-770)...
Synairgen aerosolised IFN-beta shows efficacy against pneumonia
UK-based respiratory drug discovery and development company, Synairgen has presented the positive data from its pre-clinical study investigating the effectiveness of aerosolised interferon...
Lallemand, GM Pharmaceuticals launch Ismigen in Georgia
Lallemand Pharma and GM Pharmaceuticals have introduced new oral vaccine Ismigen in Georgia, US, to prevent acute exacerbations in chronic obstructive pulmonary...
Vertex's Kalydeco shows efficacy against cystic fibrosis
Data from a Phase III trial of Vertex Pharmaceuticals' Kalydeco (ivacaftor) has been published ion the New England Journal of...
Alios BioPharma and Versitech partner for influenza therapy
Alios BioPharma has signed an exclusive worldwide licensing agreement with Versitech to develop, manufacture and market medication to combat influenza...
Tetraphase wins respiratory antibiotic contract
The National Institute of Allergy and Infectious Diseases in the US has awarded a $36m contract to Tetraphase to develop TP-271, an antibiotic for respiratory...
ChemoCentryx commences CCX168 drug trial
ChemoCentryx has initiated a Phase II clinical trial for CCX168, an orally-administered small molecule for the treatment of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis...
Kissei Pharmaceutical to support MN-221 development programme
Japan's Kissei Pharmaceutical said it will pay MediciNova $2.5m to support further clinical development of MN-221 for the treatment of acute exacerbations of asthma or chronic obstructive...
The Native Antigen Company launches new Bordetella pertussis toxin
The Native Antigen Company, contract service provider to the in vitro diagnostics industry based in Oxford, UK, has launched a new purified Bordetella pertussis...
Novavax RSV vaccine Phase 1 trial shows efficacy
A Phase I clinical study conducted by Novavax has demonstrated positive top-line results of its respiratory syncytial virus (RSV) fusion (F) recombinant nanoparticle vaccine...
MicroDose doses first patient in respiratory syncytial virus drug trial
MicroDose Therapeutx has dosed its first patient in a Phase I clinical trial of MDT-637, an inhalable antiviral fusion inhibitor designed to treat respiratory syncytial...
